The changing landscape of systemic therapy in the treatment of synchronous metastatic hormone-sensitive prostate cancer

医学 醋酸阿比特龙酯 多西紫杉醇 前列腺癌 内科学 癌症 全身疗法 肿瘤科 雄激素剥夺疗法 乳腺癌
作者
Edward Lambert,Nicolaas Lumen,Valerie Fonteyne,Daan De Maeseneer,Sofie Verbeke,Geert Villeirs,Kathia De Man,Charles Van Praet
出处
期刊:Clinical Genitourinary Cancer [Elsevier]
标识
DOI:10.1016/j.clgc.2022.11.001
摘要

To describe the changes in systemic treatments (ST) of synchronous metastatic hormone-sensitive prostate cancer (mHSPC) patients in a "real-world" setting and to explore reasons why contemporary standard of care (SOC) was not administrated to the patient.Since 2014, we prospectively register mHSPCpatients. Patients were grouped in 4 time periods: group 1 (Time period 1, January 2014-July 2015), group 2 after introduction of docetaxel (Time period 2, August 2015-July 2017), group 3 after introduction of abiraterone acetate (Time period 3, August 2017-February 2018) and group 4 after introduction of apalutamide (Time period 4, March 2018-October 2021). For every time period, we evaluated the initiated additional ST. In case patients received treatment that differed from contemporary SOC according to guidelines, reasons for this difference were explored.In total, 243 patients were included. A progressive decline in ADT monotherapy from 85% to 29% over time was observed. The proportion of patients receiving additional STs increased from 34% to 59%. Forty percent of patients were not treated according to contemporary SOC, but this percentage varied strongly per time period (10%, 67%, 53%, and 32% from time period 1 to time period 4 respectively). Reasons for these variations were heterogenous and varied across the 4 time periods. Patients being unfit for treatment and treating physicians failing to consider additional STs were the most prevalent reasons. The proportion of patients unfit for additional ST decreased from 18% to 4% over time.Use of ADT monotherapy declined gradually after the introduction of additional systemic treatments. The proportion of patients unfit for additional ST declined as more treatments became available. Although compliance to SOC increased over time, these real-world data show that adherence to clinical practice guidelines remains suboptimal. Efforts should be made by clinicians to increase the adherence to practice guidelines.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
怕孤单的牛排完成签到,获得积分10
3秒前
Maer完成签到 ,获得积分10
3秒前
乐乐应助Hai采纳,获得10
4秒前
6秒前
阿湫完成签到,获得积分10
7秒前
Ren发布了新的文献求助10
8秒前
9秒前
萧水白应助笑点低的怀莲采纳,获得10
9秒前
kchen85完成签到,获得积分0
10秒前
10秒前
思源应助奥格诺采纳,获得10
11秒前
王大禹发布了新的文献求助10
11秒前
link171完成签到,获得积分10
11秒前
华仔应助Ssyong采纳,获得10
12秒前
张腾腾完成签到,获得积分10
13秒前
zhangxr发布了新的文献求助10
13秒前
14秒前
骞骞完成签到 ,获得积分10
14秒前
15秒前
追寻的莺完成签到 ,获得积分10
16秒前
甜蜜小之发布了新的文献求助10
16秒前
Hai发布了新的文献求助10
16秒前
yule完成签到 ,获得积分10
17秒前
18秒前
巫马完成签到,获得积分10
18秒前
刘蛋完成签到,获得积分10
18秒前
王粒完成签到,获得积分10
19秒前
fwt发布了新的文献求助10
20秒前
21秒前
24秒前
所所应助勤恳易谙采纳,获得10
24秒前
小马甲应助饱满绮波采纳,获得10
27秒前
Akim应助Amber采纳,获得10
27秒前
科目三应助Mike14采纳,获得10
27秒前
tt。完成签到,获得积分10
27秒前
卓飞扬发布了新的文献求助10
29秒前
29秒前
甜蜜小之完成签到,获得积分10
29秒前
29秒前
小田发布了新的文献求助20
31秒前
高分求助中
Sustainability in Tides Chemistry 2800
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
юрские динозавры восточного забайкалья 800
English Wealden Fossils 700
Foreign Policy of the French Second Empire: A Bibliography 500
Chen Hansheng: China’s Last Romantic Revolutionary 500
XAFS for Everyone 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3143821
求助须知:如何正确求助?哪些是违规求助? 2795450
关于积分的说明 7815080
捐赠科研通 2451485
什么是DOI,文献DOI怎么找? 1304498
科研通“疑难数据库(出版商)”最低求助积分说明 627251
版权声明 601419